News
NVSEF
150.00
NaN%
--
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
Seeking Alpha · 19h ago
Weekly Report: what happened at NVSEF last week (0330-0403)?
Weekly Report · 2d ago
Is Trump to blame for delayed drug launches in Europe
Seeking Alpha · 03/31 16:28
Weekly Report: what happened at NVSEF last week (0323-0327)?
Weekly Report · 03/30 09:31
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
Seeking Alpha · 03/23 20:41
Weekly Report: what happened at NVSEF last week (0316-0320)?
Weekly Report · 03/23 09:29
Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
Seeking Alpha · 03/22 12:58
China signals broader market access, trade rebalancing in pitch to global business
Seeking Alpha · 03/22 12:27
Weekly Report: what happened at NVSEF last week (0309-0313)?
Weekly Report · 03/16 09:29
Regeneron: Fairly Valued Now After A Stellar Upswing
Seeking Alpha · 03/11 13:47
Weekly Report: what happened at NVSEF last week (0302-0306)?
Weekly Report · 03/09 09:30
Weekly Report: what happened at NVSEF last week (0223-0227)?
Weekly Report · 03/02 09:30
Novartis picks Texas to build next radioligand therapy site
Seeking Alpha · 02/25 13:31
Weekly Report: what happened at NVSEF last week (0216-0220)?
Weekly Report · 02/23 09:29
Trump says tariffs prompt Novartis to expand U.S. manufacturing
Seeking Alpha · 02/20 11:50
Novartis inks licensing deal worth up to $1.8B for oral peptide drugs
Seeking Alpha · 02/18 14:21
Weekly Report: what happened at NVSEF last week (0209-0213)?
Weekly Report · 02/16 09:29
GMOI: This International ETF Is Off To A Strong Start
Seeking Alpha · 02/12 21:01
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
Seeking Alpha · 02/11 15:00
AVDE: Diversified And Effective Active ETF At A Low Cost
Seeking Alpha · 02/10 17:39
More
Webull provides a variety of real-time NVSEF stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVSEF
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.